Login
$BFRI
$0.59 +$0.02 (3.79%) After hours

$BFRI SEC Filings

Filed On Filing
13 Nov 2026 10-Q
13 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 8-K: Results of Operations and Financial Condition

WOBURN, Mass., November 13, 2026 — Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today re...

30 Oct 2026 25-NSE
14 Sep 2026 8-K: Other Events

Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera’s photodynamic therapy plat...

13 Aug 2026 10-Q
13 Aug 2026 8-K: Results of Operations and Financial Condition

WOBURN, Mass., August 13, 2026 — Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today repo...

12 Aug 2026 SCHEDULE 13G/A
29 Jul 2026 Form 4: Luebbert Hermann, Director

Received 62,500 shares by exercise or conversion

29 Jul 2026 Form 4: Leffler Eugene Frederick, Chief Financial Officer

Received 31,250 shares by exercise or conversion

22 Jul 2026 S-8
22 Jul 2026 10-K/A
17 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 11, 2026, Biofrontera Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). Proxies for the Annual Meeting were solicited pursuant to Regulation 14A under the Securities Exchange Act of 1934, and th...

14 May 2026 10-Q
14 May 2026 8-K: Results of Operations and Financial Condition

Woburn, MA (May 14, 2026) (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ: BFRI) (the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported ...

30 Apr 2026 Proxy statement: annual meeting on June 11, 2026
19 Mar 2026 10-K
19 Mar 2026 8-K: Results of Operations and Financial Condition

Woburn, MA (March 19, 2026) (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ:BFRI) (the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported...

09 Mar 2026 8-K: Regulation FD Disclosure

Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris

06 Mar 2026 Form 4: Luebbert Hermann, Director

Granted 125,000 Restricted Stock Units · Granted 125,000 Employee stock option (right to buy) · Received 137,500 shares by exercise or conversion

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support